The abstract submission site is now closed. The abstract deadline was December 1, 2020. Abstract acceptance or non-acceptance decision notices will be distributed to abstract presenting authors by the first week of January 2021. Following the release of the notifications, more information will be provided to Poster and Platform Session presenters regarding timelines and procedures for delivering the posters and presentations.

Video with Online Planner Login Instructions

2021 SOT Virtual Poster Presentations Sneak Preview

Virtual Poster Sessions

The Virtual Annual Meeting will maximize exposure to research through a state-of-the-art poster presentation platform.

As a poster presenter, you can expect to (1) showcase your research in multiple ways for multiple days: digital posters allow for optimal viewing through a built-in magnifying feature, a short audio narration, and on-demand poster viewing beyond the Poster Session time frame to extend the poster’s impact; (2) interact with attendees during designated author-attended times; and (3) maintain the integrity of your research: attendees are prohibited from capturing content displayed on their screen, in accordance with the Annual Meeting policies.

Abstract Acceptances

You will receive your acceptance notice and session timing/instructions by email in late December; please keep your email information up-to-date within the Abstract Submission System to ensure receipt of acceptance. Once poster and platform presentations have been scheduled, the complexity of the program planning process prevents any changes in the type of session, time, or location of any presentation. There are no exceptions.

Abstract Withdrawals

Abstract acceptance obligates the author to pay the meeting registration fee and present the abstract in the assigned Poster or Platform Session. Written notification of withdrawal of an abstract must be received by SOT Headquarters by January 8 if the abstract cannot be included in the Annual Meeting materials. Any withdrawal requests made after January 8 will be honored by SOT Headquarters; however, based on the date of the request, the abstract may be included in the materials, and a “Withdrawn by Author” sign will appear on the poster board.

A poster display runs perpendicular to the the camera along the left-hand side of the photo. A man who is turned toward the camera is pointing at the poster display. He is speaking to a man standing to his left. This second man is seen in profile. In the background are other poster displays and people looking at them.

Authorship and Sponsorship

Authors are permitted as the presenting author on only one abstract for the meeting, which includes presentations for Scientific Sessions. There is no restriction on the number of co-authorships. The SOT Scientific Program Committee reserves the right to require consolidation of multiple abstracts submitted from a single study. Each abstract selected for the program must be presented by the presenting author.

If none of the authors is an SOT member, sponsorship by a Full or Associate member or by an approved sponsoring organization is required. If an SOT member is unavailable to sponsor the abstract and at least one author is a member of an organization approved for offering sponsorship, the author can indicate a sponsoring organization instead of SOT member in the abstract system. By sponsoring the abstract, the sponsor acknowledges that the research has been done according to the SOT Code of Ethics. SOT members may sponsor an unlimited number of abstracts.

The approved sponsoring organizations are:

What the Abstract Should and Should Not Include

The Scientific Program Committee reviews each abstract that is submitted. The scientific quality of the abstracts presented contributes substantially toward making the SOT Annual Meeting the leading international forum for new toxicologic research. Therefore, there is a standard for abstract acceptance. The following guidelines apply to each abstract:

For acceptance, abstracts describing the results of experimental studies must answer two questions (“What was done?” and “What was found?”) and must contain the following:

  • A statement of the rationale and scope of the study presented
  • A brief description of the experimental procedures
  • The data that resulted from the study
  • The principal conclusion(s) based on interpretation of the results

Additionally, authors should consider the following when developing the abstract:

  • Test compounds utilized in the study should be identified in the abstract. In cases where the length of the proper chemical name precludes its use, a manufacturer’s identification number, etc., may be acceptable, provided the structure and chemical identity of the compound are included in the presentation. Abstracts will not be accepted if the authors are unable to disclose the chemical identity of the compound(s) used in the study.
  • When describing your research or assessment approaches, please refrain from using introductory phrases such as “will be presented.” Phrases such as “results/data will be discussed” convey no information as to the outcome of the studies and are unacceptable.
  • It can be challenging to describe results of “big data” studies within the confines of a 2,300-character abstract. Instead, include specific examples of findings to help meet the requirement for description of data.
  • All animal experimentation must be carried out in accordance with the Society’s Guiding Principles in the Use of Animals in Toxicology.
  • All abstracts submitted with human testing require that IRB protocol has been followed and approval obtained.

In the case of studies that do not describe laboratory or field experiments, such as reports on educational, ethics, legal, or social initiatives, authors should:

  • Describe the research or assessment approach instead of experimental procedures.
  • Summarize the study’s results or findings explicitly.
  • Clearly articulate the implications for stakeholders.

In addition, abstracts describing new initiatives or science policy in the regulatory community must clearly describe the impact on the practice of toxicology and/or risk assessment. Care should be taken to clearly distinguish between statements based on documented facts versus opinions. Literature surveys or reviews and background materials are insufficient in and of themselves.



  • Air Pollution Toxicology
  • Air Pollution: Biomass
  • Air Pollution: Ozone
  • Air Pollution: Particulate Matter
  • Alternatives to Mammalian Models
  • Animal Models
  • Autoimmunity/Hypersensitivity
  • Bioinformatics
  • Biological Modeling
  • Biomarkers
  • Biotransformation/Cytochrome P450
  • Carcinogenesis
  • Cardiovascular Toxicology/Hemodynamics
  • Cell Death/Apoptosis
  • Chemical Threats and Bioterrorism
  • Climate Change and Effects
  • Clinical and Translational Toxicology
  • Computational Toxicology and Data Integration
  • Developmental and Juvenile Toxicology
  • Developmental Basis of Adult Disease
  • Disposition/Pharmacokinetics
  • Drugs of Abuse
  • Ecotoxicology
  • Education, Ethical, Legal, and Social Issues
  • Emerging Technologies
  • Endocrine Toxicology
  • Epidemiology and Public Health
  • Epigenetics
  • Exposure Assessment/Biomonitoring
  • Food Safety/Nutrition
  • Gene Regulation/Signal Transduction
  • Genotoxicity/DNA Repair
  • Immunotoxicity
  • Inflammation
  • Kidney
  • Liver
  • Medical Devices
  • Metals
  • Mixtures
  • Nanotoxicology, General
  • Nanotoxicology, In Vitro
  • Nanotoxicology, In Vivo
  • Natural Disasters
  • Natural Products
  • Neurodegenerative Disease
  • Neurodegenerative Disease: Parkinson’s Disease
  • Neurotoxicity, Developmental
  • Neurotoxicity, General
  • Neurotoxicity, Metals
  • Neurotoxicity, Pesticides
  • Nonchemical Stressors and Cumulative Risk Assessment
  • Ocular Toxicology
  • Oxidative Injury and Redox Biology
  • Perfluorinated Alkyl Substances (PFAS)
  • Persistent Organic Pollutants (POPs)
  • Pesticides
  • Receptors
  • Regulation/Policy
  • Reproductive Toxicology
  • Respiratory Toxicology
  • Risk Assessment
  • Safety Assessment: Nonpharmaceutical
  • Safety Assessment: Pharmaceutical—Drug Development
  • Safety Assessment: Pharmaceutical—Drug Discovery
  • Skin
  • Stem Cell Biology and Toxicology
  • Systems Biology and Toxicology

Abstracts that are selected to be presented orally, as opposed to as a poster, are scheduled into Platform Sessions, where speakers have 15 minutes each to deliver a PowerPoint presentation of their abstract.

You may indicate your interest in this type of presentation at the beginning of the submission process by selecting the option for “Platform or Poster” on the “Presentation Preference” screen. The programming of your abstract into a particular session type will be at the discretion of the Scientific Program Committee.

For the 2021 Annual Meeting, there will not be a late-breaking abstract submission period. This is due to the abstract deadline being extended to December 1, which occurred in response to scientific research disruptions created by the COVID-19 pandemic.

If none of the authors on your abstract is an SOT member, sponsorship by a Full or Associate member is required. By sponsoring the abstract, the sponsor acknowledges that the research has been completed in adherence with the SOT Code of Ethics. If there is no Full or Associate SOT member available, if at least one author is a member of an approved sponsoring organization, you may indicate that in the Abstract Submission System. A full list of approved sponsoring organizations can be found the “Authorship and Sponsorship” section on this web page.

At this time, SOT can only accept payment by credit card. Accepted credit cards include Visa, MasterCard, Discover, and American Express.

A “Print Receipt” option will appear in the Abstract Submission System once the abstract fee payment has been approved. Receipts are also emailed however you are encouraged to check your Junk or Spam folder if you do not receive an emailed receipt within 30 minutes of submitting an abstract.

Refunds are not offered for any abstracts that have been submitted for the SOT Annual Meeting. The submission fee covers the costs associated with processing and reviewing the abstracts.

The abstract submission fee is $50, payable only by credit or debit card.

Using the Abstract System

The system has a 120-minute time-out feature. After 120 minutes of inactivity, the system will automatically log you out. If this happens, your entries up to that point WILL BE SAVED, and you will be returned to the place where you left off when you log back in. If you get a “Page Cannot Be Displayed” error, you have probably been logged out.

This depends on your browser. For most browsers, you may copy and paste your full title and abstract into the appropriate fields in the abstract system from an MS Word document, and the special characters will be preserved in the abstract system. A special character tool also is available in the abstract system. However, if there is hidden coding embedded in the document you are copying from, the special characters may be replaced with a question mark or other symbols when the abstract is loaded into the Abstract Submission System. Be sure to review the summary page of your abstract submission in the system and check the special characters to make sure they are intact.

If you have any conflicts of interest that you need to disclose, please indicate them in the author step. If your abstract is accepted, you must include those conflicts on a disclosure slide in your platform presentation or make the disclosure on your poster.

The submission site does not recognize your SOT membership login information and requires a separate login. However, when you create your Abstract Submission System login, you may use your SOT credentials.

Upon starting the process to submit an abstract, you will be automatically assigned a control ID number. Once you have completed the abstract submission process, please keep a copy of the submission confirmation for your records, including your control ID number. You will need your control ID number to communicate with SOT Headquarters and/or the Tech Support team about a specific abstract.